CD8-Positive T-Lymphocytes
Showing 1 - 25 of >10,000
COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive Trial in Houston (biological, drug, procedure)
Active, not recruiting
- COL6A3 Positive
- +3 more
- Aldesleukin
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 3, 2022
HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Myxoid Liposarcoma Trial in Houston
Active, not recruiting
- HLA-A*0201 Positive Cells Present
- +3 more
- Aldesleukin
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Feb 25, 2022
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Active, not recruiting
- Platinum-Resistant Fallopian Tube Carcinoma
- +11 more
- Aldesleukin
- +3 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jul 13, 2022
Frequency and of Regulatory Function of Positive T Lymphocytes
Completed
- Allergic Asthma
- +2 more
- double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse
-
Nantes, Pays De La Loire, FranceNantes University Hospital
Sep 10, 2021
Acute Myeloid Leukemia, EBV-Positive Neoplastic Cells Present, HLA-A*0201 Positive Cells Present Trial in Seattle (Aldesleukin,
Terminated
- Acute Myeloid Leukemia
- +4 more
- Aldesleukin
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 15, 2021
EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma Trial in Korea,
Recruiting
- EBV Associated Extranodal NK/T-cell Lymphoma
- EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma
- EBViNT Cell
-
Seoul, Gangnam-gu, Korea, Republic of
- +7 more
Jul 7, 2022
Circulating Cluster of Differentiation 4 Positive 28 Null T
Not yet recruiting
- Autoimmune Hemolytic Anemia
- (no location specified)
Jan 31, 2023
Metastatic Malignant Tumor in the Liver, Metastatic Uveal Melanoma Trial in Houston (Aldesleukin, Autologous CD8+
Active, not recruiting
- Metastatic Malignant Neoplasm in the Liver
- Metastatic Uveal Melanoma
- Aldesleukin
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 20, 2023
HNSCC, Melanoma, Gynecologic Cancer Trial in Portland (DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2)
Recruiting
- HNSCC
- +5 more
- DP CD8 TIL
- +2 more
-
Portland, OregonProvidence Portland Medical Center
Jun 5, 2023
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma Trial in Houston (CD30.CAR-EBVST cells)
Recruiting
- Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
- Classical Hodgkin Lymphoma
- CD30.CAR-EBVST cells
-
Houston, Texas
- +1 more
Jul 20, 2022
Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Taiyuan (CEA-targeted CAR-T cells)
Recruiting
- Gastric Cancer
- +6 more
- CEA-targeted CAR-T cells
-
Taiyuan, Shanxi, China
- +1 more
Aug 24, 2023
Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present, Recurrent Non-Small Cell Lung Carcinoma Trial in
Terminated
- Advanced Pleural Malignant Mesothelioma
- +10 more
- Aldesleukin
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 16, 2021
Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Wuhu (CEA-targeted CAR-T cells)
Recruiting
- Gastric Cancer
- +7 more
- CEA-targeted CAR-T cells
-
Wuhu, Anhui, ChinaThe First Affiliated Hospital of Wannan Medical College
Nov 9, 2023
Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL Trial in Houston (CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T
Recruiting
- Non-Hodgkin's Lymphoma
- +2 more
- CD19.CAR-CD28Z T Cells - dose escalation 2
- CD19.CAR-CD28Z T Cells - dose escalation 1
-
Houston, Texas
- +1 more
Feb 10, 2022
Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia Trial in
Suspended
- Juvenile Myelomonocytic Leukemia
- +27 more
- CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 11, 2023
Alterations in CD8aß and CD8aa T Cell Levels in Rheumatoid
Not yet recruiting
- Rheumatoid Arthritis
- flow cytometry
- (no location specified)
Apr 12, 2023
CD70-positive Advanced Urologic Tumors Trial in Shanghai (Anti-CD70 CAR-T cells)
Recruiting
- CD70-positive Advanced Urologic Neoplasms
- Anti-CD70 CAR-T cells
-
Shanghai, Shanghai, ChinaChanghai Hospital
Aug 11, 2023
Glioblastoma Multiforme of Brain Trial in Duarte (CHM-1101 CAR-T cells)
Not yet recruiting
- Glioblastoma Multiforme of Brain
- CHM-1101 CAR-T cells
-
Duarte, CaliforniaCity of Hope Medical Center
Dec 19, 2022
Lymphoma Trial in Beijing (CD70-targeting CAR-T cells)
Recruiting
- Lymphoma
- CD70-targeting CAR-T cells
-
Beijing, Biotherapeutic Department Of Chinsese PLA Gereral Hospital, ChinaChina
Jul 9, 2023
Pancreatic Ductal Adenocarcinoma, NSCLC, Colorectal Cancer Trial (AFNT-211)
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- +4 more
- (no location specified)
Oct 23, 2023
Solid Tumor, Adult Trial in Beijing (CD70-targeting CAR-T cells)
Recruiting
- Solid Tumor, Adult
- CD70-targeting CAR-T cells
-
Beijing, Iotherapeutic Department Of Chinsese PLA Gereral Hospital, ChinaChina
Jul 8, 2023
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CD19 specific Chimeric Antigen Receptor T Cell
-
Columbus, OhioNationwide Children's Hospital
Mar 9, 2023
CD4+T Lymphocytes in Primary Nephrotic Syndrome With Infection
Recruiting
- Nephrotic Syndrome
- +2 more
- The study is an observational study without intervention
-
Zhuhai, Guangdong, Chinathe fifth affiliated hospital of SUN YAT-SEN university
Nov 20, 2022
Metastatic Colorectal Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma Trial in
Not yet recruiting
- Metastatic Colorectal Adenocarcinoma
- +5 more
- Bendamustine
- +11 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 12, 2023